DocProcess joins AGENA3000, as Morphosis Capital and Founders complete successful exit
DocProcess, a Romanian technology company specialized in business process automation, founded by entrepreneurs Daniela and Liviu Apolozan, becomes part of AGENA3000, a French provider of data management and e-invoicing solutions. The transaction also marks the full exit of Morphosis Capital from DocProcess, its first investment from Fund I.
“DocProcess is a company with remarkable potential that complements perfectly the digital solutions portfolio of AGENA3000. Its platform is among the most advanced on the market, and the team behind it has demonstrated not only strong technological expertise but also a deep understanding of today’s business landscape. We were particularly impressed by the vision of the founding team and their innovative approach to process automation, which aligns fully with our mission to build a more connected and efficient digital future. Going forward, integrating DocProcess will allow us to accelerate our international expansion while relying on its proven infrastructure and capabilities,” said Sébastien Trichet, President of AGENA3000.
Founded in 2005, DocProcess has developed its SaaS-based Business Ecosystem Automation (BEA) platform, enabling companies to digitize and streamline critical processes such as procure-to-pay, order-to-cash, e-invoicing, and e-transport. Today, DocProcess serves more than 3,500 clients across sectors including finance, procurement, retail, logistics, healthcare, insurance, and energy. Its customer portfolio includes multinationals such as Carrefour, Unilever, Mondelez, and Lactalis, as well as leading Romanian entrepreneurial companies like E-Boda, Altex, and Flanco. In 2024, the company achieved revenues of over EUR 4.2 million and EBITDA of EUR 1.1 million.
“For us, DocProcess has always been more than just a business – it was a mission to redefine how companies collaborate and automate critical processes. We are proud of what we have accomplished over the past 20 years together with our exceptional team and grateful to our clients and partners for their trust. This transaction marks the beginning of a new stage for DocProcess with AGENA3000, an organization that shares our vision for the future of digitalization. We also thank Morphosis Capital for believing in us and supporting the company’s development. We truly value everything we have achieved together and we are confident that the DocProcess story will continue with even greater strength in this new chapter,” stated Daniela and Liviu Apolozan, founders of DocProcess.
The acquisition by AGENA3000 provides DocProcess with the opportunity to accelerate its international expansion, particularly in France and across other European markets, while also expanding into the enterprise segment. Its team of 43 employees, based in Bucharest, Paris, and Grenoble, will join the French group, strengthening AGENA3000’s expertise in procure-to-pay and order-to-cash processes, while offering DocProcess’ clients access to a broader suite of solutions in data management and e-invoicing.
“DocProcess had the right ingredients from the very beginning – a solid platform and founders determined to scale it across Europe, benefitting from the favorable market context. Over the past years, with the support of the Morphosis team, the company had the resources and structure needed to evolve into a profitable SaaS business with international reach. Now, as part of AGENA3000, DocProcess is well-positioned to grow further in France and broaden its reach into the enterprise segment. We are grateful to Daniela, Liviu and the extended DocProcess team for their partnership and proud to have been part of this journey,” said Simona Gemeneanu, Partner at Morphosis Capital.
This transaction marks the second full exit of Morphosis Capital Fund I, following the sale of its entire stake in Dr. Leahu Dental Clinics to Regina Maria in June 2023. In addition, the fund has completed two partial exits through strategic partnerships with international private equity funds: Integral Venture Partners in Medima Health and Innova Capital in EMI. The DocProcess transaction underscores Morphosis Capital’s strategy of backing ambitious entrepreneurs, supporting them in scaling their companies, and ensuring smooth transitions to strategic or financial investors.
The transaction was facilitated by Cristian Mîndru and Mihaela Posircă from Act Legal, on behalf of Morphosis Capital and DocProcess, while AGENA3000 was supported by law firms Wolf Theiss and Cornet Vincent Ségurel as well as GTA Tax, in the capacity of a tax advisor.
This operation is funded by the European Union – NextGenerationEU with the financial backing of the Government of Romania under the Romania Recovery Equity Fund and benefits from the support of the European Union under the InvestEU Fund.
____________________
About AGENA3000
In a world where data is omnipresent, AGENA3000, a software publisher and integrator, has made it its mission to exchange and enhance data. For more than 45 years, its solutions — EDI (Electronic Data Interchange), E-Invoicing, TPM (Trade Promotion Management), PIM (Product Information Management) , PDM (Product Data Management), and ConsoTrust (data enhancement through AI) — have been helping companies succeed in their digital transformation. Although distinct, these solutions are complementary and share a common foundation: data.
Today, the group has 250 employees, serves over 6,000 clients across Europe and North America, and has been experiencing strong growth for a decade. The group generates 30% of its revenue internationally and is present in 5 countries (France, Canada, Tunisia, the Netherlands, and Romania).
About DocProcess
DocProcess is the market leader in Business Ecosystem Automation in Romania. The company offers a wide range of services including P2P (purchase-to-pay), O2C (order-to-cash), e-archiving, e-invoicing, and contract lifecycle management, helping transform all functional areas of a business. Established in 2005, DocProcess has an international footprint, with offices in Romania and France (R&D in Grenoble and Commercial in Paris) and a portfolio of over 3,500 reputable clients including Altex, Carrefour, Coca Cola, Dante International, Emag Retail, Interbrands, Flanco, Intersport France and Lactalis.
About Morphosis Capital
Morphosis Capital Partners BV is a private equity firm established by four entrepreneurs, Simona Gemeneanu, Gabriela Dumitru, Dragos Petre, and Andrei Gemeneanu, supported by an expanded investment team. The fund aims to contribute to developing and transforming Romanian and Central European SMEs. Morphosis Capital invests in high-growth Romanian and CEE companies from sectors such as healthcare, technology, niche manufacturing, consumer products and retail, and B2B services, which have a strong potential for international expansion and an EBITDA between 1 and 5 million euros. Morphosis Capital Fund I’s portfolio includes Medima Health, EMI, Cronos Med and Stay Fit Gym. In 2023, the fund completed its first full exit by selling its minority stake in Dr. Leahu Dental Clinics to Regina Maria, followed by full exit from DocProcess to AGENA3000 in 2025. Fund II’s portfolio currently includes Romania Education Alliance, supermarket chain La Cocos and EnduroSat.
The European Investment Fund (EIF), the leading financing platform for European SMEs, co-financed through the Regional Operational Programme, the NextGenerationEU with the financial backing of the Government of Romania under the Romania Recovery Equity Fund and the InvestEU Fund of the European Union, is the anchor investor in Morphosis Capital. International and local institutional investors and entrepreneurs, as well as the founders themselves, are co-investors in the fund. www.morphosiscapital.com